Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1225

1.

Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.

Liu L, Yang H, Lou Y, Wu JY, Miao J, Lu XY, Gao JQ.

Int J Pharm. 2019 Feb 25;557:170-177. doi: 10.1016/j.ijpharm.2018.12.053. Epub 2018 Dec 28.

PMID:
30597264
2.

Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity.

Shang H, Zhou A, Jiang J, Liu Y, Xie J, Li S, Chen Y, Zhu X, Tan H, Li J.

Acta Biomater. 2018 Sep 15;78:178-188. doi: 10.1016/j.actbio.2018.07.045. Epub 2018 Aug 2.

PMID:
30076991
3.

Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

Sladek S, Kearney C, Crean D, Brama PAJ, Tajber L, Fawcett K, Labberte MC, Leggett B, Brayden DJ.

Drug Deliv Transl Res. 2018 Oct;8(5):1421-1435. doi: 10.1007/s13346-018-0557-x.

PMID:
29947020
4.

Salmon Calcitonin Attenuates Degenerative Changes in Cartilage and Subchondral Bone in Lumbar Facet Joint in an Experimental Rat Model.

Gou Y, Tian F, Kong Q, Chen T, Li H, Lv Q, Zhang L.

Med Sci Monit. 2018 May 7 [revised 2018 Jan 1];24:2849-2857. doi: 10.12659/MSM.910012.

5.

Synergistic and non-synergistic effects of salmon calcitonin and omega - 3 fatty acids on antioxidant, anti-inflammatory, and haematological indices in diabetic rats.

Adeyemi WJ, Olayaki LA.

Biomed Pharmacother. 2018 Mar;99:867-875. doi: 10.1016/j.biopha.2018.01.085. Epub 2018 Feb 20.

PMID:
29710486
7.

In Vitro-In Vivo Evaluation of an Oral Ghost Drug Delivery Device for the Delivery of Salmon Calcitonin.

Hibbins AR, Govender M, Indermun S, Kumar P, du Toit LC, Choonara YE, Pillay V.

J Pharm Sci. 2018 Jun;107(6):1605-1614. doi: 10.1016/j.xphs.2018.02.004. Epub 2018 Feb 13.

PMID:
29452142
8.

Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia.

Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL.

Calcif Tissue Int. 2018 Jun;102(6):666-670. doi: 10.1007/s00223-017-0382-0. Epub 2018 Jan 30.

9.

Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats.

Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G, Tore F.

Clin Exp Pharmacol Physiol. 2018 Jun;45(6):536-546. doi: 10.1111/1440-1681.12915. Epub 2018 Feb 13.

PMID:
29344989
10.

Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.

Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Reiner DJ, Pham T, Nguyen CTN, Turner CA, Olivos DR, Wimmer ME, Schmidt HD, Hayes MR.

Neuropharmacology. 2017 Sep 1;123:67-79. doi: 10.1016/j.neuropharm.2017.05.024. Epub 2017 May 25.

11.

Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release.

Cao S, Liu Y, Shang H, Li S, Jiang J, Zhu X, Zhang P, Wang X, Li J.

J Control Release. 2017 Jun 28;256:182-192. doi: 10.1016/j.jconrel.2017.04.014. Epub 2017 Apr 13.

PMID:
28414150
12.

The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc).

Whiting L, McCutcheon JE, Boyle CN, Roitman MF, Lutz TA.

Physiol Behav. 2017 Jul 1;176:9-16. doi: 10.1016/j.physbeh.2017.03.023. Epub 2017 Mar 22.

13.

Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.

Reiner DJ, Mietlicki-Baase EG, Olivos DR, McGrath LE, Zimmer DJ, Koch-Laskowski K, Krawczyk J, Turner CA, Noble EE, Hahn JD, Schmidt HD, Kanoski SE, Hayes MR.

Biol Psychiatry. 2017 Dec 1;82(11):828-838. doi: 10.1016/j.biopsych.2016.12.028. Epub 2017 Jan 10.

14.

Response of trabecular bone, thyroid C and follicular cells to synthetic salmon calcitonin in middle-aged orchidectomized male rats.

Filipović B, Šošić-Jurjević B, Ajdžanović V, Živanović J, Ristić N, Trifunović S, Milošević V.

J Anat. 2017 Jun;230(6):787-795. doi: 10.1111/joa.12600. Epub 2017 Feb 20.

15.

Anhydrous reverse micelle nanoparticles: new strategy to overcome sedimentation instability of peptide-containing pressurized metered-dose inhalers.

Huang Z, Wu H, Yang B, Chen L, Huang Y, Quan G, Zhu C, Li X, Pan X, Wu C.

Drug Deliv. 2017 Nov;24(1):527-538. doi: 10.1080/10717544.2016.1269850.

PMID:
28181839
16.

Nasal osteoma and inhaled salmon calcitonin: Coincidence or consequence?

Peña-Rodríguez ZA, Haro-García M, Benito-Navarro JR.

Acta Otorrinolaringol Esp. 2017 Nov - Dec;68(6):366-368. doi: 10.1016/j.otorri.2016.09.004. Epub 2017 Jan 6. English, Spanish. No abstract available.

17.

Platypus and opossum calcitonins exhibit strong activities, even though they belong to mammals.

Yamashita T, Udagawa N, Thirukonda GJ, Uehara S, Yamauchi H, Suzuki N, Li F, Kobayashi Y, Takahashi N.

Gen Comp Endocrinol. 2017 May 15;246:270-278. doi: 10.1016/j.ygcen.2017.01.001. Epub 2017 Jan 4.

PMID:
28062306
18.
19.

Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.

Aguirre TAS, Aversa V, Rosa M, Guterres SS, Pohlmann AR, Coulter I, Brayden DJ.

J Control Release. 2016 Sep 28;238:242-252. doi: 10.1016/j.jconrel.2016.07.047. Epub 2016 Jul 30.

PMID:
27480451
20.

A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.

Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, Valter I, Qvist P, Lau E, Riis BJ, Christiansen C, Karsdal MA; SMC021 investigators.

Bone. 2016 Oct;91:122-9. doi: 10.1016/j.bone.2016.07.019. Epub 2016 Jul 25.

PMID:
27462009

Supplemental Content

Loading ...
Support Center